首页 | 官方网站   微博 | 高级检索  
     

阿昔莫司联合氯吡格雷对高脂血症患者血脂及颈动脉斑块的影响
引用本文:姜爱雯,杜佩珊,汤建华,石金铮,刘云宁,张鹤鸣.阿昔莫司联合氯吡格雷对高脂血症患者血脂及颈动脉斑块的影响[J].中国现代应用药学,2020,37(5):600-603.
作者姓名:姜爱雯  杜佩珊  汤建华  石金铮  刘云宁  张鹤鸣
作者单位:河北北方学院附属第一医院, 河北 张家口 075000,张家口市第一医院, 河北 张家口 075000,河北北方学院附属第一医院, 河北 张家口 075000,河北北方学院附属第一医院, 河北 张家口 075000,河北北方学院附属第一医院, 河北 张家口 075000,河北北方学院附属第一医院, 河北 张家口 075000
基金项目:河北省卫生计生委医学科学研究项目(20160355)
摘    要:目的探讨阿昔莫司联合氯吡格雷治疗高脂血症并颈动脉斑块的临床疗效。方法选取高脂血症并颈动脉斑块患者66例,随机分为阿昔莫司组和阿昔莫司+氯吡格雷组。阿昔莫司组给予阿昔莫司0.25 g,口服,bid;阿昔莫司+氯吡格雷组给予阿昔莫司0.25 g,口服,bid+氯吡格雷75 mg,口服,qd。2组患者疗程均为8周,观察2组患者治疗前后血浆总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、颈动脉内膜中层厚度(IMT)、血流变参数、肿瘤坏死因子-α(TNF-α)、白细胞介素-1(IL-1)和白细胞介素-6(IL-6)情况。结果治疗前2组患者TC、TG、HDL-C、LDL-C、IMT、血流变参数、TNF-α、IL-1和IL-6比较,差异均无统计学意义。治疗后2组患者TC、LDL-C、颈动脉斑块面积、血浆纤维蛋白原、TNF-α、IL-6均显著低于同组治疗前,且阿昔莫司+氯吡格雷组显著低于阿昔莫司组,差异有统计学意义(P<0.05)。2组患者对IMT均有改善作用,但与治疗前无显著性差异。结论阿昔莫司联合氯吡格雷对高脂血症患者血脂具有显著改善作用,并可显著减少患者颈动脉斑块,改善患者病情,具有临床诊疗价值。

关 键 词:阿昔莫司  氯吡格雷  高脂血症  颈动脉斑块
收稿时间:2019/4/14 0:00:00

Effect of Acipimox Combined with Clopidogrel on Blood Lipid and Carotid Plaque in Patients with Hyperlipidemia
JIANG Aiwen,DU Peishan,TANG Jianhu,SHI Jinzheng,LIU Yunning and ZHANG Heming.Effect of Acipimox Combined with Clopidogrel on Blood Lipid and Carotid Plaque in Patients with Hyperlipidemia[J].The Chinese Journal of Modern Applied Pharmacy,2020,37(5):600-603.
Authors:JIANG Aiwen  DU Peishan  TANG Jianhu  SHI Jinzheng  LIU Yunning and ZHANG Heming
Affiliation:The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China,Zhangjiakou First Hospital, Zhangjiakou 075000, China,The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China,The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China,The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China and The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China
Abstract:OBJECTIVE To investigate the clinical effect of acipimox combined with clopidogrel in the treatment of hyperlipidemia and carotid plaque. METHODS Sixty six patients with hyperlipidemia and carotid plaque were randomly divided into acipimox group and acipimox+clopidogrel group. Acipimox group was given acipimox 0.25 g, bid, orally, acipimox+clopidogrel group was given acipimox 0.25 g, bid, orally and clopidogrel 75 mg, qd, orally. Treatment course of 2 groups lasted for 8 weeks. The plasma level of TC, TG, HDL-C, LDL-C, IMT, parameters of hemorheology, TNF-α, IL-1 and IL-6 were observed in 2 groups before and after treatment. RESULTS TC, TG, HDL-C, LDL-C, IMT, parameters of hemorheology, TNF-α, IL-1 and IL-6 had no statistical significance between 2 groups before treatment. TC, LDL-C, carotid plaque area, plasma fibrinogen, TNF-α and IL-6 of 2 groups after treatment were significantly lower than before, and those of acipimox+clopidogrel group were significantly lower than acipimox group(P<0.05). IMT of 2 groups was improved, but no statistical significance between 2 groups compared with before treatment. CONCLUSION Acipimox combined with clopidogrel can significantly improve blood lipids in patients with hyperlipidemia, significantly reduce carotid plaque in patients, and improve the patient’s condition, which has clinical diagnosis and treatment value.
Keywords:acipimox  clopidogrel  hyperlipemia  carotid plaque
本文献已被 维普 等数据库收录!
点击此处可从《中国现代应用药学》浏览原始摘要信息
点击此处可从《中国现代应用药学》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号